肿瘤细胞治疗研究
英文原题：Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting.
TIL（肿瘤浸润淋巴细胞）疗法作为过继性细胞疗法（ACT）中极具前景的一种形式，已在治疗晚期黑色素瘤方面取得成功。
TIL（肿瘤浸润淋巴细胞）疗法是一种极具前景的过继细胞疗法（ACT），已成功用于治疗晚期黑色素瘤。值得注意的是，创新的TIL单药和联合方案已使多种实体瘤患者获得持久临床应答并改善生存。本文总结2025年美国临床肿瘤学会（ASCO）年会上报告的实体瘤TIL疗法近期进展，重点介绍单药疗法lifileucel、LM103、OBX-115、GT101、GT300、GT201和HS-IT101，以及与溶瘤腺病毒TILT-123或帕博利珠单抗联合的策略。
Tumor-infiltrating lymphocyte (TIL) therapy, a highly promising form of adoptive cell therapy (ACT), has demonstrated success in treating advanced melanoma. Notably, innovative TIL-based monotherapies and combination regimens have provided durable clinical responses and survival benefits for patients with various solid tumors. This article summarizes recent advances in TIL therapy for solid tumors presented at the 2025 ASCO Annual Meeting, highlighting monotherapies such as Lifileucel, LM103, OBX-115, GT101, GT300, GT201, and HS-IT101, as well as combination strategies with the oncolytic adenovirus TILT-123 or pembrolizumab.
MEMBER ACCOUNT
登录成功会直接打开下一页。
